% | $
Quotes you view appear here for quick access.

Teva Pharmaceutical Industries Limited Message Board

  • oedd1159 oedd1159 Jan 4, 2014 1:46 PM Flag

    Credit Suisse

    I a recent released study Credit Suisse forecasted that Copaxone Sales would decrease in 2019 to just 400 M from the current 4 B .If that is so that means a yearly reduction in revenues of 360 M roughtly around 9%

    Now chose a recently issue revenue decrease by Teva say from 4 q 2012 to 1 q 2013 and you will realize that in spite of a revenue slide of 6.6 % price did not follow suit in fact Teva price increased from 37 to 39.5 .

    I think that if Teva keeps pouring new pharmacologic entities into the stream here and there in the next 7 years i think that will do . (its R&D budget will ensure that ) Imao.


    * Credit Suisse also foresees an increase in sales of Laquinimod by 1B by the same period.

    ** Credit Suisse was one of the best stock analyst performers for 2013.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
51.66+0.07(+0.14%)May 27 4:02 PMEDT